证券代码：301331 证券简称：恩威医药 公告编号：2025-032 恩威医药股份有限公司 关于公司高级管理人员减持股份的预披露公告 公司高级管理人员陈磊保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 特别提示： 恩威医药股份有限公司（以下简称"公司"）副总裁陈磊先生持有公司股份 65,118 股，占公司总股本比例 0.0633%（占剔除已回购股份后总股本比例 0.0644%），计划在本减持计划预披露公告之日起十五个交易日后的三个月内（窗 口期不减持），以集中竞价方式减持公司股份不超过 16,279 股，占公司总股本比 例 0.0158%（占剔除已回购股份后总股本比例 0.0161%），若在本减持计划公告 日至减持时间区间届满日期间公司有送股、资本公积金转增股本、配股等股份变 动事项，上述拟减持股份数量将进行相应调整。 恩威医药股份有限公司（以下简称"公司"）于近日收到公司副总裁陈磊先 生出具的《关于股份减持计划的告知函》，现将有关情况公告如下： 二、减持计划内容 | 股东名称 | 职务 | | | 占 ...

Core Viewpoint - The antiviral oral liquid market is experiencing significant growth driven by the rising incidence of viral diseases and increasing health awareness among consumers, with a projected market size increase from 1.1 billion yuan in 2020 to 1.469 billion yuan in 2024, reflecting a compound annual growth rate of 7.5% [1][12]. Industry Overview - Antiviral oral liquids are common traditional Chinese medicine formulations, primarily composed of ingredients like Banlangen, Shigao, and Lugen, used for treating viral infections such as influenza and respiratory infections [3][5]. - The industry has evolved since the 1980s, transitioning from basic herbal formulations to more sophisticated products due to technological advancements, leading to improved efficacy and safety [5]. Market Dynamics - The demand for antiviral oral liquids is increasing due to the high prevalence of viral diseases and an aging population, alongside a shift in consumer perception of these products as essential for daily health protection [1][12]. - The rise of e-commerce platforms has further facilitated market growth by providing convenient access to these products [1][12]. Industry Chain - The industry chain consists of upstream raw material cultivation, production equipment, and packaging materials; midstream involves the manufacturing of antiviral oral liquids; and downstream includes sales through hospitals, pharmacies, clinics, and e-commerce platforms [8]. Competitive Landscape - The market is becoming increasingly competitive with numerous companies entering the field, necessitating continuous innovation and marketing efforts to stand out [13]. - Key players in the industry include ST Xiangxue, China Resources Sanjiu, Kangyuan Pharmaceutical, and others, each with unique product offerings and market strategies [1][13]. Development Trends - There is significant growth potential in the central and rural markets, where the penetration of antiviral oral liquids is currently low due to insufficient medical resources [21]. - Future innovations in nanotechnology and targeted drug delivery systems are expected to enhance product efficacy and reduce side effects, driving further advancements in the industry [22]. - The market is likely to see increased concentration as leading companies leverage technology and brand development to capture larger market shares, while new entrants may adopt innovative strategies to compete [23].

证券代码：301331 证券简称：恩威医药 公告编号：2025-031 恩威医药股份有限公司 关于控股股东一致行动人增持公司股份计划实施完毕暨增 持结果的公告 公司控股股东一致行动人成都杰威企业管理有限公司保证向本 公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 特别提示： 1、增持计划的基本情况：恩威医药股份有限公司（以下简称"公司"）于 2025 年 1 月 21 日披露了《关于控股股东一致行动人取得金融机构增持贷款承诺暨增 持公司股份计划的公告》（公告编号：2025-002），公司控股股东一致行动人成 都杰威企业管理有限公司（以下简称"成都杰威"）基于对公司未来持续稳定发展 的信心和长期投资价值的认可，为增强投资者信心，成都杰威计划自增持计划公 告之日起 6 个月内，通过集中竞价的方式增持公司 A 股股份。总体增持金额不 低于人民币 3,600 万元，不超过人民币 7,200 万元。 2、增持计划实施情况：截至 2025 年 7 月 17 日，成都杰威已通过深圳证 券交易所证券交易系统集中竞价交易方式累计增 ...

法律意见书 北京金杜（成都）律师事务所 关于恩威医药股份有限公司 控股股东一致行动人增持公司股份之 致：恩威医药股份有限公司 根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和 国证券法》（以下简称《证券法》）、《上市公司收购管理办法》（以下简称《收 购管理办法》）等有关规定，北京金杜（成都）律师事务所（以下简称本所）接 受恩威医药股份有限公司（以下简称公司）之委托，就公司控股股东之一致行动 人成都杰威企业管理有限公司（以下简称增持人）增持公司股份（以下简称本次 增持）所涉相关事项，出具本法律意见书。 为出具本法律意见书，本所及本所律师根据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等有关规定及本法 律意见书出具日以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤 勉尽责和诚实信用原则，对本次增持所涉及的事实和法律问题进行了充分的核查 验证，保证本法律意见书所认定的事实真实、准确、完整，所发表的结论性意见 合法、准确，不存在虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任。 本法律意见书的出具已得到公司及增持人的如下保证： 1、其已经提供了本所 ...

恩威医药股份有限公司（以下简称"公司"）于 2025 年 1 月 21 日披露了《关 于控股股东一致行动人取得金融机构增持贷款承诺暨增持公司股份计划的公告》 （公告编号：2025-002），公司控股股东一致行动人成都杰威企业管理有限公司 （以下简称"成都杰威"）基于对公司未来持续稳定发展的信心和长期投资价值的 认可，为增强投资者信心，成都杰威计划自增持计划公告之日起 6 个月内，通过 集中竞价的方式增持公司 A 股股份。总体增持金额不低于人民币 3,600 万元，不 超过人民币 7,200 万元。 证券代码：301331 证券简称：恩威医药 公告编号：2025-030 恩威医药股份有限公司 关于控股股东一致行动人增持股份触及 1%暨增持计划进展 情况的公告 公司控股股东一致行动人成都杰威企业管理有限公司保证向本 公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 4.承诺、计划等履行情况 | | 是☑ 否□ | | --- | --- | | | 公司于 年 月 日披露了《关于控股股东一致行 2025 1 21 | ...

Group 1 - The announcement details the pledge and release of shares by the controlling shareholder, Chengdu Enwei Investment (Group) Co., Ltd., which holds 29,733,200 shares, accounting for 28.90% of the company's total share capital as of June 20, 2025 [2] - The total number of pledged shares exceeds 50% of the shares held by the shareholder and its concerted parties, with 14,890,836 shares maturing in the next six months, representing 21.10% of their holdings and 14.47% of the total share capital, with a corresponding financing balance of 13.38 million [2] - The company confirms that the pledge does not affect its operations, governance, or financial stability, and there are no non-operational fund occupations or violations that harm the company's interests [2][3] Group 2 - The financial condition of the shareholder is reported to be good, with sufficient repayment capability, and there is no risk of forced liquidation or transfer of pledged shares [3] - The company commits to timely disclosure of any significant changes regarding the pledged shares in accordance with legal and regulatory requirements [4]

证券代码：301331 证券简称：恩威医药 公告编号：2025-029 恩威医药股份有限公司 关于控股股东部分股份质押及解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： 2 | 股东名称 | 持股 | 持 | 本次 | 本次 | 占其 | 占公 | 已质押股份情 | | 未质押股份情 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 数量 | 股 | 质押 | 质押 | 所持 | 司总 | 况 | | 况 | | | | （股 | 比 | 前质 | 后质 | 股份 | 股本 | 已质押 | 占已 | 未质押 | 占未 | | | ） | 例 | 押股 | 押股 | 比例 | 比例 | 股份限 | 质押 | 股份限 | 质押 | | | | | 份数 | 份数 | | | 售和冻 | 股份 | 售和冻 | 股份 | | | | | 量 | 量 | | | 结、标 | 比例 | 结数量 | ...

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]

证券代码：301331 证券简称：恩威医药 公告编号：2025-028 恩威医药股份有限公司 恩威医药股份有限公司（以下简称：公司）全资子公司河南信心药业有限公司（以 下简称：信心药业）于近日取得了药品监管部门换发的《药品生产许可证》，现将有 关情况公告如下： 一、换发的《药品生产许可证》基本信息 关于全资子公司取得换发的《药品生产许可证》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 企业名称：河南信心药业有限公司 注册地址：郑州市二七区嵩山南路 81 号嵩山园区综合楼南楼第五层楼 社会信用代码：91410100170007221L 法定代表人：庄严 企业负责人：陈世超 质量负责人：王珏 生产地址和生产范围： 郑州市陇海中路 56 号：片剂，颗粒剂，散剂，丸剂(大蜜丸、水蜜丸、水丸、浓 缩丸、蜡丸)，合剂(口服液)，糖浆剂，煎膏剂(含中药前处理及提取)***四川省成都市 双流区双华路三段 458 号(受托生产企业为四川恩威制药有限公司)前处理车间中药前 处理提取生产线、制剂车间合剂生产线：清热解毒口服液(每支装 10ml；国药准字 Z41021003 ...

Group 1 - The A-share controllable nuclear fusion sector experienced a short-term surge, with significant gains in related stocks [1] - Silver and non-ferrous metals stocks, including Baili Electric, hit the daily limit up, indicating strong market interest [1] - Other companies such as Zhongzhou Special Materials, Xue Ren Co., Changfu Co., Wangzi New Materials, and Shun Na Co. also saw increases in their stock prices, reflecting a broader trend in the sector [1]